Top Markets
Coin of the day
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc.

6492
Clasificación en acciones #21774
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Precio por acción
$1.11
Última sincronización: 2026-08-21
Capitalización bursátil
$100.55M
Cambio (1 día)
-7.69%
Cambio (1 año)
-7.17%
País
TW
Comercio Senhwa Biosciences, Inc. (6492)

Categoría

Precio 6492 con Capital del mercado a B
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
6492
$1.11
Capitalización de mercado de Senhwa Biosciences, Inc.(6492)
Capitalización bursátil: $100.55M
A fecha de August 2026, Senhwa Biosciences, Inc. tiene una capitalización de mercado de $100.55M. Esto convierte a Senhwa Biosciences, Inc. en la 21774th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Senhwa Biosciences, Inc. desde 2014 hasta 2026
6492 en comparación con los más populares 5 títulos stocks
Precio por 6492 Activo B Capital del mercado en B Resultados
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$57,355.39 $100.55M
$5.211T +5,182,899.16%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$50,040.67 $100.55M
$4.547T +4,521,894.34%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$45,811.46 $100.55M
$4.162T +4,139,716.21%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$39,541.61 $100.55M
$3.593T +3,573,132.23%
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.
$30,737.65 $100.55M
$2.793T +2,777,550.53%